Transarterial radioembolization for liver tumors as neoadjuvant therapy: three case reports

Abstract

Transarterial radioembolization (TARE) with yttrium-90 microspheres is a palliative locoregional treatment, minimally invasive for liver tumors. The neoadjuvant aim of this treatment is still controversial, however, selected cases with lesions initially considered unresectable have been enframed as candidates for curative therapy after hepatic transarterial radioembolization. We report three cases in which the hepatic transarterial radioembolization was used as neoadjuvant therapy in an effective way, allowing posterior potentially curative therapies.

Transarterial Selective Internal Radiation Therapy with Yttrium-90 for Liver Metastatic Urothelial Carcinoma of the Ureter as a Bridging Therapy to Immunotherapy: A Case Report with a 10-Year Follow-Up

“…With the development of glass and resin Y90 microspheres in the 1990s, several studies demonstrated its potential role for advanced-stage hepatocellular carcinoma [16]. Nowadays, its applications have evolved for several types of malignancies and for different situations in the treatment pathway for patients with cancer, not more restricted to the salvage setting for patients with chemorefractory disease [11,12,[17][18][19].…”

“…The commercial dosimetry software, MIM SurePlan LiverY90 ® (MIM Software Inc., Cleveland, OH) was used for absorbed dose calculation [10, 11, 15]. The tumors received 199 and 70 Gy at V70 (V70 = mean tumor dose to top 70% of tumor volume), respectively.…”

“…This locoregional therapy was used from palliative care to neoadjuvant treatment in the treatment of several types of liver metastatic disease with encouraging outcomes [10][11][12]. Herein, we present a first-of-its-kind case where SIRT was successfully used in combination with other pre-established treatment options for metastatic upper urinary tract urothelial carcinoma.…”

Locoregional therapies for the treatment of locally advanced hepatocellular carcinoma

“…However, it is a costly treatment and is not widely available. Although SIRT is considered a palliative treatment, there have been reports of patients in whom HCC was downstaged after SIRT and who subsequently underwent tumor resection, liver transplantation, or both, thus being given the possibility of a cure ( 10 ) .…”